{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:13:03Z","timestamp":1790017983587,"version":"4.0.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Intravenous and intranasal ketamine have been shown to be effective therapeutic options in patients suffering from treatment-resistant depression (TRD). The use of sublingual (SL), rapid dissolve ketamine tablets (RDT) offers a novel approach for delivery for mental health indications. This study assessed the effectiveness and safety of self-administration of off-label, SL, rapid dissolve ketamine tablets (RDT) at-home for depression and anxiety. Intake scores on the Generalized Anxiety Disorder Screener (GAD-7) and Patient Health Questionnaire (PHQ-9) were compared to scores after treatments of three doses of ketamine RDT, and after six doses of ketamine RDT. After three doses of SL ketamine, 47.6% of patients showed a significant decrease in PHQ-9 scores, and 47.6% of patients showed a significant reduction in GAD-7 scores. Reduction rates were higher in those patients who completed a clinically recommended six doses of RDT ketamine. This study demonstrates that SL ketamine is a novel, safe, and effective treatment for TRD and treatment-resistant anxiety. SL ketamine offers an alternative therapeutic approach to IV ketamine when treating those with TRD.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.992624","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T05:43:10Z","timestamp":1664343790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use"],"prefix":"10.3389","volume":"13","author":[{"given":"Kazi","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Struthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Sankarabhotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"B1","unstructured":"Symptoms of depression among adults: United States, 201918\n            VillarroelMA\n          33054920NCHS Data Brief2020"},{"key":"B2","unstructured":"Prevalence of depression among adults aged 20 and over: United States, 2013\u2013201618\n            BrodyDJ\n          NCHS Data Brief2018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jad.2018.04.016","article-title":"Treatment-resistant depression and suicidality","volume":"235","author":"Bergfeld","year":"2018","journal-title":"J Affect Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12991-019-0248-0","article-title":"All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population","volume":"18","author":"Li","year":"2019","journal-title":"Ann Gen Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ajp.2017.02.005","article-title":"The multiple diagnoses of comorbid anxiety disorders and higher interpersonal sensitivity predict treatment-resistant depression","volume":"26","author":"Mogi","year":"2017","journal-title":"Asian J Psychiatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"204512532092247","DOI":"10.1177\/2045125320922474","article-title":"Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study","volume":"10","author":"Glue","year":"2020","journal-title":"Ther Adv Psychopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapsychiatry.2017.1273","article-title":"Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014","volume":"74","author":"Bushnell","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3389\/fpsyt.2020.00844","article-title":"The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication","volume":"11","author":"Andrashko","year":"2020","journal-title":"Front Psychiatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1017\/S0033291707002012","article-title":"Comorbid major depression and generalized anxiety disorders in the national comorbidity survey follow-up","volume":"38","author":"Kessler","year":"2008","journal-title":"Psychol Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0165-0327(01)00354-8","article-title":"Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database","volume":"68","author":"Khan","year":"2002","journal-title":"J Affect Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J Psychoact Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S2215-0366(17)30102-5","article-title":"Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight","volume":"4","author":"Singh","year":"2017","journal-title":"Lancet Psychiatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/B978-0-12-821033-8.00005-8","article-title":"\u201cOverview of ketamine for major depression: efficacy and effectiveness.,\u201d","author":"Bahji","year":"2021","journal-title":"ketamine for treatment-resistant depression. Elsevier"},{"key":"B15","doi-asserted-by":"publisher","first-page":"110060","DOI":"10.1016\/j.pnpbp.2020.110060","article-title":"Increased use of ketamine for the treatment of depression: benefits and concerns","volume":"104","author":"Na","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jad.2021.06.032","article-title":"Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: a systematic review","volume":"293","author":"Ng","year":"2021","journal-title":"J Affect Disord."},{"key":"B17","unstructured":"Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia618\n            HaasDA\n            HarperDG\n          1308374Anesth Prog.391992"},{"key":"B18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/0165-0173(94)00014-G","article-title":"The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias","volume":"20","author":"Ellison","year":"1995","journal-title":"Brain Res Brain Res Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"710338","DOI":"10.3389\/fpsyt.2021.710338","article-title":"An integrative approach to ketamine therapy may enhance multiple dimensions of efficacy: improving therapeutic outcomes with treatment resistant depression","volume":"12","author":"Muscat","year":"2021","journal-title":"Front Psychiatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/bja\/aer221","article-title":"Ketamine: new uses for an old drug?","volume":"107","author":"Hirota","year":"2011","journal-title":"Br J Anaesthes."},{"key":"B22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: a paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron."},{"key":"B23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: january 2009 \u2013 January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J Affect Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"648691","DOI":"10.3389\/fpsyg.2021.648691","article-title":"Intranasal ketamine for depression in adults: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"12","author":"An","year":"2021","journal-title":"Front Psychol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J Affect Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"513068","DOI":"10.3389\/fpsyt.2021.513068","article-title":"Subcutaneous ketamine in depression: a systematic review","volume":"12","author":"Cavenaghi","year":"2021","journal-title":"Front Psychiatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00213-021-05825-8","article-title":"Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: a meta-analysis","volume":"238","author":"Conley","year":"2021","journal-title":"Psychopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"Collins","year":"2010","journal-title":"Biol Psychiatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1177\/0269881118760660","article-title":"Repeated intranasal ketamine for treatment-resistant depression \u2013 the way to go? Results from a pilot randomised controlled trial","volume":"32","author":"G\u00e1lvez","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"CD011611","DOI":"10.1002\/14651858.CD011611.pub3","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder","volume":"10","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"B32","first-page":"137","article-title":"An update on the efficacy and tolerability of oral ketamine for major depression: a systematic review and meta-analysis","volume":"50","author":"Nu\u00f1ez","year":"2020","journal-title":"Psychopharmacol Bull."},{"key":"B33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"AJP."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e17352","DOI":"10.7759\/cureus.17352","article-title":"Efficacy and safety of intranasal esketamine in treatment-resistant depression in adults: a systematic review","volume":"13","author":"Sapkota","year":"2021","journal-title":"Cureus."},{"key":"B35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jad.2020.11.123","article-title":"Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review","volume":"281","author":"Veraart","year":"2021","journal-title":"J Affect Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2019.02.044","article-title":"Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: a meta-analysis of randomized controlled trials","volume":"250","author":"Zheng","year":"2019","journal-title":"J Affect Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"19f12820","DOI":"10.4088\/JCP.19f12820","article-title":"Oral Ketamine for depression, 1: pharmacologic considerations and clinical evidence","volume":"80","author":"Andrade","year":"2019","journal-title":"J Clin Psychiatr"},{"key":"B38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00213-017-4786-3","article-title":"Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study","volume":"235","author":"Hartberg","year":"2018","journal-title":"Psychopharmacology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1017\/S1461145713000485","article-title":"Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression","volume":"16","author":"Lara","year":"2013","journal-title":"Int J Neuropsychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2147\/NDT.S88569","article-title":"Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review","volume":"11","author":"Matsumoto","year":"2015","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B41","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bdi.12941","article-title":"The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder","volume":"22","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/jps.2600710516","article-title":"Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans","volume":"71","author":"Clements","year":"1982","journal-title":"J Pharml Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bcp.12264","article-title":"The absolute bioavailability of racemic ketamine from a novel sublingual formulation: bioavailability of sublingual ketamine","volume":"77","author":"Rolan","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jad.2022.07.004","article-title":"At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial","volume":"314","author":"Hull","year":"2022","journal-title":"J Affect Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","article-title":"Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression","volume":"155","author":"Shiroma","year":"2014","journal-title":"J Affect Disord."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.4088\/JCP.16l11277","article-title":"The antidepressant effect of repeat dose intravenous ketamine is delayed by concurrent benzodiazepine use","volume":"78","author":"Albott","year":"2017","journal-title":"J Clin Psychiatr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.drudis.2016.01.016","article-title":"Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity","volume":"21","author":"Gerhard","year":"2016","journal-title":"Drug Discov Today."},{"key":"B48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Mathew SJ. Ketamine for depression: where do we go from here?","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol Psychiatr."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.992624\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T05:43:16Z","timestamp":1664343796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.992624\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":48,"alternative-id":["10.3389\/fpsyt.2022.992624"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.992624","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"article-number":"992624"}}